DYNAVAX TECHNOLOGIES CORP Uncategorized Contracts & Agreements
42 Contracts & Agreements
- Letter Agreement No. 2, dated October 31, 2022, by and among the Company, Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited (Filed With SEC on November 3, 2022)
- Letter Agreement, dated August 30, 2022, by and among the Company, Zhejiang Clover Biopharmaceuticals, Inc., Clover Biopharmaceuticals (Hong Kong) Co., Limited and Sichuan Clover... (Filed With SEC on November 3, 2022)
- Letter Agreement, dated October 29, 2021, by and among the Company, Valneva Scotland Limited and Valneva Austria GmbH (Filed With SEC on February 28, 2022)
- Amended and Restated Dynavax Technologies Corporation 2021 Inducement Award Plan (Filed With SEC on August 4, 2021)
- First Amendment to Agreement, dated May 3, 2021, between the Company and Coalition for Epidemic Preparedness Innovations (Filed With SEC on August 4, 2021)
- Form of Confirmation for Capped Call Transactions (Filed With SEC on May 13, 2021)
- Agreement, dated January 29, 2021 between Company and Coalition for Epidemic Preparedness Innovations (Filed With SEC on February 25, 2021)
- President and Chief Operating Officer Letter, dated December 13, 2019, between the Company and David Novak (Filed With SEC on March 11, 2020)
- Chief Executive Officer Letter, dated December 13, 2019, between the Company and Ryan Spencer (Filed With SEC on March 11, 2020)
- Co-President Officer Letter, dated May 30, 2019, between the Company and Ryan Spencer (Filed With SEC on August 7, 2019)
- Co-President Officer Letter, dated May 30, 2019, between the Company and David Novack (Filed With SEC on August 7, 2019)
- Sublicense Agreement, effective as of February 16, 2018, by and between the Company and Merck, Sharp & Dohme Corp (Filed With SEC on May 9, 2018)
- AMENDMENT No. 7 (Filed With SEC on March 8, 2016)
- AMENDMENT No. 6 (Filed With SEC on March 5, 2015)
- SEE REVERSE SIDE FOR RESTRICTIVE LEGEND(S) (Filed With SEC on November 1, 2013)
- DYNAVAX TECHNOLOGIES CORPORATION (Filed With SEC on May 3, 2013)
- AMENDMENT No. 4 (Filed With SEC on March 12, 2012)
- [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKEDBY BRACKETS, HAS BEEN OMITTED ANDFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO... (Filed With SEC on April 30, 2009)
- FORM OF RIGHT CERTIFICATE (Filed With SEC on November 6, 2008)
- ISS work by changing or reprogramming the immune responses that cause disease rather than just treating the symptoms of disease (Filed With SEC on March 17, 2008)
- ISS work by changing or reprogramming the immune responses that cause disease rather than just treating the symptoms of disease (Filed With SEC on March 17, 2008)
- Current assets (Filed With SEC on November 6, 2007)
- COLEY PHARMACEUTICAL GROUP, INC. (Filed With SEC on August 3, 2007)
- Current assets (Filed With SEC on November 3, 2006)
- Exhibit No (Filed With SEC on October 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on August 4, 2006)
- Current assets (Filed With SEC on May 5, 2006)
- AIC for Ragweed Allergy. We have developed a novel injectable product candidate to treat ragweed allergy that we call AIC. AIC is an immunotherapeutic intervention for ragweed... (Filed With SEC on March 18, 2005)
- DYNAVAX TECHNOLOGIES CORPORATION (Filed With SEC on February 11, 2004)
- DYNAVAX TECHNOLOGIES CORPORATION (Filed With SEC on December 1, 2003)
- DYNAVAX TECHNOLOGIES CORPORATION (Filed With SEC on December 1, 2003)
